120 related articles for article (PubMed ID: 26424199)
1. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
[TBL] [Abstract][Full Text] [Related]
2. Risk of Enzyme- and Transporter-Mediated Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2022: A Detailed Analysis of In Vitro and Clinical Data Available in New Drug Application Reviews.
Yu J; Wang Y; Ragueneau-Majlessi I
Clin Ther; 2024 May; ():. PubMed ID: 38734524
[TBL] [Abstract][Full Text] [Related]
3. Potential of patient-reported outcomes as nonprimary endpoints in clinical trials.
Gnanasakthy A; Lewis S; Clark M; Mordin M; DeMuro C
Health Qual Life Outcomes; 2013 May; 11():83. PubMed ID: 23675876
[TBL] [Abstract][Full Text] [Related]
4. Statin Drug-Drug Interactions: Pharmacokinetic Basis of FDA Labeling Recommendations and Comparison Across Common Tertiary Clinical Resources.
Mease J; Ramamoorthy A; Yang X; Madabushi R; Pfuma Fletcher E; Zineh I
J Clin Pharmacol; 2024 Jun; 64(6):704-712. PubMed ID: 38299698
[TBL] [Abstract][Full Text] [Related]
5. A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database.
Hachad H; Ragueneau-Majlessi I; Levy RH
Hum Genomics; 2010 Oct; 5(1):61-72. PubMed ID: 21106490
[TBL] [Abstract][Full Text] [Related]
6. The Cancer Drug Fraction of Metabolism Database.
Hua L; Chiang CW; Cong W; Li J; Wang X; Cheng L; Feng W; Quinney SK; Wang L; Li L
CPT Pharmacometrics Syst Pharmacol; 2019 Jul; 8(7):511-519. PubMed ID: 31206254
[TBL] [Abstract][Full Text] [Related]
7. The U.S. FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective.
Jiang Y; Liu P; Qiu Z; Zhou M; Cheng M; Yang T
Eur J Med Chem; 2024 Jun; 275():116593. PubMed ID: 38889609
[TBL] [Abstract][Full Text] [Related]
8. Metrabase: a cheminformatics and bioinformatics database for small molecule transporter data analysis and (Q)SAR modeling.
Mak L; Marcus D; Howlett A; Yarova G; Duchateau G; Klaffke W; Bender A; Glen RC
J Cheminform; 2015; 7():31. PubMed ID: 26106450
[TBL] [Abstract][Full Text] [Related]
9. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.
Yu J; Zhou Z; Tay-Sontheimer J; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2018 Jun; 46(6):835-845. PubMed ID: 29572333
[TBL] [Abstract][Full Text] [Related]
10. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C-dependent regulation of human hepatic drug transporter expression.
Mayati A; Le Vee M; Moreau A; Jouan E; Bucher S; Stieger B; Denizot C; Parmentier Y; Fardel O
Biochem Pharmacol; 2015 Dec; 98(4):703-17. PubMed ID: 26462574
[TBL] [Abstract][Full Text] [Related]
12. Correction: Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Aravena C; Labarca G; Venegas C; Arenas A; Rada G
PLoS One; 2015; 10(10):e0140288. PubMed ID: 26439742
[No Abstract] [Full Text] [Related]
13. Functional Characterization of Carrier-Mediated Transport of Pravastatin across the Blood-Retinal Barrier in Rats.
Fujii S; Setoguchi C; Kawazu K; Hosoya K
Drug Metab Dispos; 2015 Dec; 43(12):1956-9. PubMed ID: 26431714
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
[TBL] [Abstract][Full Text] [Related]
15. Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients.
Huang H; Dai HP; Kang J; Chen BY; Sun TY; Xu ZJ
Medicine (Baltimore); 2015 Oct; 94(42):e1600. PubMed ID: 26496265
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models.
Kotsampasakou E; Brenner S; Jäger W; Ecker GF
Mol Pharm; 2015 Dec; 12(12):4395-404. PubMed ID: 26469880
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?
Slizgi JR; Lu Y; Brouwer KR; St Claire RL; Freeman KM; Pan M; Brock WJ; Brouwer KL
Toxicol Sci; 2016 Jan; 149(1):237-50. PubMed ID: 26507107
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.
Durmus S; Lozano-Mena G; van Esch A; Wagenaar E; van Tellingen O; Schinkel AH
Mol Pharm; 2015 Dec; 12(12):4259-69. PubMed ID: 26474710
[TBL] [Abstract][Full Text] [Related]
19. Albumin and Uptake of Drugs in Cells: Additional Validation Exercises of a Recently Published Equation that Quantifies the Albumin-Facilitated Uptake Mechanism(s) in Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling Research.
Poulin P; Haddad S
J Pharm Sci; 2015 Dec; 104(12):4448-4458. PubMed ID: 26457988
[TBL] [Abstract][Full Text] [Related]
20. Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy.
Alqahtani S; Kaddoumi A
PLoS One; 2015; 10(10):e0139762. PubMed ID: 26431339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
